数字护理平台Veris Health完成250万美元股权融资-动脉网

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

CISION 等信源发布 2025-06-24 20:01



可切换为仅中文







Private placement yields

私募收益率

$2.5 million

250万美元

from the sale of Veris Health common stock at a

从出售 Veris Health 普通股中获得的

$35 million

3500万美元

pre-money valuation.

投前估值。

NEW YORK

纽约

，

June 24, 2025

2025年6月24日

/PRNewswire/ --

PAVmed Inc.

PAVmed公司

(Nasdaq:

（纳斯达克：

PAVM

肺动静脉畸形

) ('PAVmed' or the 'Company'), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc. ('Veris'), today announced the completion of a private placement equity financing directly into Veris, yielding .

）（“PAVmed”或“公司”），一家在医疗器械、诊断和数字健康领域运营的多元化商业阶段医疗技术公司，及其控股子公司Veris Health Inc.（“Veris”）今天宣布已完成对Veris的私募股权融资，筹集金额为。

$2.5 million

250万美元

in proceeds (gross and net). This supplements a prior

收益（毛利和净利）。这是对之前的一个补充

$2.4 million

240万美元

financing

融资

completed

已完成

earlier this year.

今年早些时候。

继续阅读

Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. (PRNewsfoto/PAVmed Inc.)

Veris Health Inc. 是一家数字健康公司，专注于通过使用可植入的生物传感器进行远程患者监控，这些传感器具有无线通信功能，并配备了一套定制的连接外部设备，以实现更个性化的癌症护理。（PRNewsfoto/PAVmed Inc.）

Veris sold shares of its common stock at

Veris 出售了其普通股的股份

$1.40

1.40美元

per share, reflecting a pre-money valuation of approximately

每股，反映投资前估值约为

$35 million

3500万美元

. Veris will use the proceeds to advance its implantable physiological monitor through FDA clearance, expected in 2026, and for general corporate purposes. For each share of Veris common stock purchased, the investor received a warrant to purchase an additional share at an exercise price of

Veris将利用这笔资金推动其可植入生理监测仪通过FDA审批，预计将在2026年完成，并用于一般公司用途。对于每一份购买的Veris普通股，投资者获得了以行使价购买额外股份的认股权证。

$1.40

1.40美元

per share. The warrants are callable by Veris within 60 days of FDA clearance of its implantable physiological monitor. Additional capital raised through warrant exercises will be used to accelerate commercialization of the device once clearance is secured.

每股。认股权证在Veris公司获得FDA对其植入式生理监测仪的批准后的60天内可被赎回。通过认股权证行使筹集的额外资本将用于在获得批准后加速该设备的商业化进程。

'This financing, at an attractive valuation, reflects strong investor confidence in Veris' commercial potential and represents an important milestone for both PAVmed and Veris,' said

“这笔融资估值颇具吸引力，反映了投资者对Veris商业潜力的强烈信心，同时标志着PAVmed和Veris的一个重要里程碑，”

Lishan Aklog

李山·阿克洛格

, M.D.

，医学博士

, Chairman and CEO of PAVmed and Executive Chairman of Veris Health. 'Veris is now sufficiently capitalized to fund development of its implantable physiological monitor through FDA clearance and subsequent commercial launch. The monitor—designed to enhance personalized care in conjunction with the Veris Cancer Care Platform—will serve as a key commercial differentiator.'.

，PAVmed的董事长兼首席执行官以及Veris Health的执行董事长。“Veris现在已经获得了足够的资本支持，可以资助其可植入生理监测器通过FDA审批并随后进行商业发布。该监测器旨在与Veris癌症护理平台结合使用，以加强个性化护理，并将成为关键的商业差异化因素。”

About Veris Health

关于Veris Health

Veris Health Inc. is a digital health company whose lead product, the Veris Cancer Care Platform, is a comprehensive digital care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction..

Veris Health Inc. 是一家数字健康公司，其主导产品 Veris 癌症护理平台是一个综合性的数字护理平台，具有远程生理数据收集、症状报告、远程医疗功能以及电子健康记录集成。该平台旨在通过早期发现并发症、减少计划外住院、提供生理和临床数据的纵向趋势、数据驱动的风险管理工具以及提高患者和医疗服务提供者的满意度，来提供更个性化的癌症护理。

Cancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via an embedded cellular connection. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app.

注册该平台的癌症患者会收到一个装有Veris品牌联网医疗设备的VerisBox™，这些设备通过嵌入式蜂窝连接将生理数据传输到基于云的临床医生门户。互补的患者门户允许患者通过Veris患者智能手机应用程序向他们的癌症护理团队报告症状以及整体健康和生活质量参数。

The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted in combination with a vascular access port, which will interface with the Veris Cancer Care Platform.

该应用程序还允许患者邀请护理人员和家人参与他们的癌症治疗过程。 Veris 还在开发一种可植入的生理监测器，旨在与血管通路端口结合植入，该监测器将与 Veris 癌症护理平台进行交互。

The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance..

植入式监护仪将通过提供独立于患者依从性的远程生理数据，进一步提升该平台的临床和商业价值。

Cancer centers and oncology centers interested in learning more about Veris and the Veris Platform, please visit

有兴趣了解更多关于Veris和Veris平台的癌症中心和肿瘤学中心，请访问

www.verishealth.com

to contact a company representative.

联系公司代表。

About PAVmed

关于PAVmed

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its other subsidiary (in addition to Veris), Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard.

PAVmed Inc. 是一家多元化的商业阶段医疗技术公司，业务涉及医疗器械、诊断和数字健康领域。其另一家子公司（除 Veris 之外），Lucid Diagnostics，是一家商业阶段的癌症预防医疗诊断公司，负责销售 EsoGuard。

Esophageal DNA Test and EsoCheck

食管DNA测试和EsoCheck

Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths.

食管细胞收集装置——首个也是唯一一个用于广泛早期检测食管癌前病变的商业工具，以降低食管癌死亡风险。

For more and for more information about PAVmed, please visit

有关PAVmed的更多信息，请访问

pavmed.com

帕夫梅德公司

。

For more information about Veris Health, please visit

有关 Veris Health 的更多信息，请访问

verishealth.com

。

Forward-Looking Statements

前瞻性声明

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.

本新闻稿包含涉及风险和不确定性的前瞻性声明。前瞻性声明是指任何非历史事实的陈述。这些基于PAVmed管理层当前信念和期望的前瞻性声明受风险和不确定性影响，可能导致实际结果与前瞻性声明有所不同。

Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments.

可能导致此类差异的风险和不确定性包括但不限于：PAVmed普通股价格的波动；总体经济和市场状况；研发过程中固有的不确定性，包括将PAVmed产品推进到监管提交所需的成本和时间；监管机构是否对PAVmed的临床和临床前研究的设计和结果感到满意；PAVmed的产品是否以及何时获得监管机构的批准；PAVmed产品在获批并商业化后市场的接受程度；PAVmed根据需要筹集额外资金的能力；以及其他竞争性发展。

These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, 'Risk Factors,' in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, 'Risk Factors' in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise.

这些因素难以准确预测，甚至无法预测，其中许多因素是PAVmed无法控制的。此外，新的风险和不确定性可能不时出现，并且难以预测。有关这些重要风险和不确定性以及其他可能影响PAVmed未来运营的风险和不确定性的进一步列表和描述，请参见PAVmed最近提交给证券交易委员会的Form 10-K年度报告的第一部分第1A项“风险因素”，并可能在PAVmed最近年度报告之后提交的任何Form 10-Q季度报告的第二部分第1A项“风险因素”中进行更新。PAVmed拒绝承担任何公开更新或修订的意图或义务。

SOURCE PAVmed Inc.

来源：PAVmed Inc.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者